Clinical trialNCT05120349Active, not recruitingPhase 3Interventional

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

SponsorAstraZenecaEnrollment390Non-Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jie He, MD, PhD
The Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS)
Principal Investigator
clinicaltrials.gov ↗
Jonathan Goldman, MD
University of California, Los Angeles
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Yasuhiro Tsutani, MD, PhD
Kindai University Facility of Medicine
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

139 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
Cipolletti, Argentina
Research Site
La Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
S.C. de Bariloche, Argentina

Brazil

Research Site
Barretos, Brazil
Research Site
Belo Horizonte, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Recife, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Canada

Research Site
Vancouver, British Columbia, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Toronto, Canada

China

Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Harbin, China
Research Site
Jinan, China
Research Site
Nanjing, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenzhen, China
Research Site
Suzhou, China
Research Site
Taiyuan, China
Research Site
Xi'an, China

99 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Feb 2022
Primary completion: 2 Aug 2027
Completion: 1 Nov 2032
Last update posted: 6 Jul 2026
Registered enrollment: 390
Registry id: NCT05120349

Cross-registrations

EU-CTR / CTIS (EudraCT)2021-004135-89EU-CTR / CTIS (EudraCT)2023-509943-28

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.